Track topics on Twitter Track topics that are important to you
Progression-free survival was longer with sunitinib in patients with papillary and unclassified histologies, but longer with everolimus in those with chromophobe histology.
A phase II trial found that cabozantinib offers significantly better progression-free survival over sunitinib in patients with untreated advanced RCC.
US-based biopharmaceutical company Exelixis has demonstrated improvement in progression-free survival (PFS) with cabozantinib, compared to sunitinib in patients with advanced intermediate or poor risk...
Sunitinib is an oral tyrosine kinase inhibitor used for cancer treatment. Patients treated with sunitinib are at higher bleeding risk. As tyrosine kinases are essential for platelet signalling, the ef...
Molecular targeted therapy is a standard treatment for patients with advanced renal cell carcinoma (RCC). Sunitinib is one of the most common molecular-targeted drugs for metastatic RCC. Molecular mec...
To assess the efficacy and tolerability of sunitinib rechallenge in the third-line or later setting in patients with metastatic renal cell carcinoma (mRCC).
Sunitinib is an orally delivered tyrosine kinase inhibitor that exhibits antiangiogenic effects. FDA has approved sunitinib for the treatment of metastatic renal cell carcinoma. However, its efficacy ...
Sunitinib is a protein tyrosine kinase (PTK) inhibitor that has immune-modulating properties. In this context, peripheral blood mononuclear cells (PBMC), mainly constituted by lymphocytes, could be a ...